IMRA | IMARA Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.18 - 6.32
52 Week Range	0.9739 - 6.32
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	271,721
Average Volume	116,259
Shares Outstanding	26,233,789
Market Cap	165,797,546
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-03-12

Valuation
Profitability
Growth
Health
P/E Ratio	105.33
Forward P/E Ratio	N/A
EPS	0.06
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	41
Country	USA
Website	IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

IMRA's peers: ABIO, VTVT, TTOO, ERYP, ACER, IMMX, NYMX, AVTX, VVOS, TLSA

*Chart delayed

Analyzing fundamentals for IMRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IMRA Fundamentals page.

Watching at IMRA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on IMRA Technicals page.